↓ Skip to main content

Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial.

Overview of attention for article published in Obstetrics & Gynecology, February 2003
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

policy
2 policy sources
patent
13 patents
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
222 Dimensions

Readers on

mendeley
48 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial.
Published in
Obstetrics & Gynecology, February 2003
DOI 10.1016/s0029-7844(02)02712-6
Pubmed ID
Authors

Thomas Guttuso, Roger Kurlan, Michael P McDermott, Karl Kieburtz

Abstract

To evaluate whether treatment with the anticonvulsant gabapentin may be effective in reducing hot flash frequency and severity. A randomized, double-blind, placebo-controlled trial was conducted in 59 postmenopausal women with seven or more hot flashes per day examining the effects of gabapentin 900 mg per day on hot flash frequency after 12 weeks of treatment. Subsequently, study patients were enrolled in a 5-week, open-label treatment phase, during which patients could increase the dose of gabapentin to 2,700 mg per day, if needed. After 12 weeks of double-blind treatment, intention-to-treat analysis showed that gabapentin 900 mg per day was associated with a 45% reduction in hot flash frequency and a 54% reduction in hot flash composite score (frequency and severity combined into one score) from baseline, compared with 29% (P =.02) and 31% (P =.01) reductions, respectively, for placebo. Four patients (13%) in the gabapentin group and one (3%) in the placebo group withdrew from the double-blind study because of adverse events. Fifteen patients (50.0%) in the gabapentin group reported at least one adverse event, compared with eight patients (27.6%) in the placebo group. Higher, open-label gabapentin dosing was associated with 54% and 67% reductions in hot flash frequency and composite score from baseline, respectively. Gabapentin is effective in reducing hot flash frequency and severity in postmenopausal women.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 47 98%

Demographic breakdown

Readers by professional status Count As %
Other 7 15%
Student > Bachelor 6 13%
Researcher 5 10%
Student > Master 4 8%
Student > Postgraduate 4 8%
Other 4 8%
Unknown 18 38%
Readers by discipline Count As %
Medicine and Dentistry 19 40%
Nursing and Health Professions 3 6%
Psychology 2 4%
Immunology and Microbiology 1 2%
Mathematics 1 2%
Other 2 4%
Unknown 20 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 March 2022.
All research outputs
#2,864,414
of 25,377,790 outputs
Outputs from Obstetrics & Gynecology
#2,125
of 8,949 outputs
Outputs of similar age
#6,305
of 140,957 outputs
Outputs of similar age from Obstetrics & Gynecology
#5
of 45 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,949 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.0. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 140,957 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.